VIRIDIAN THERAPEUTICS INC

30 oct 2026, 20:13 UTC

Viridian Therapeutics, Inc. shares are trading sharply higher in after-market hours, maintaining a strong performance since Friday's close and above its 20-day moving average.

29 oct 2026, 20:13 UTC

Viridian Therapeutics is set to report Q3 FY2026 earnings on November 4, with an estimated EPS of $-1.03 and projected revenue of $4.9 million.

27 oct 2026, 19:51 UTC

Trading higher, approaching $20–$21 ahead of earnings report.

26 oct 2026, 19:56 UTC

Viridian Therapeutics Inc is trading sharply higher, recovering from earlier lows this week and reaching its highest point of the day.

23 oct 2026, 23:11 UTC

Viridian Therapeutics Inc saw a significant decline in after-market trading, marking its fourth consecutive session of lower closes since Friday's close.

22 oct 2026, 20:31 UTC

Viridian Therapeutics Inc is seeing a significant decline in after-market trading, deepening its losses since Thursday's close amid unusual weakness.

21 oct 2026, 20:07 UTC

Viridian Therapeutics Inc is trading higher, remaining significantly above its 20-day moving average, despite settling lower after reaching a peak earlier in the session.

20 oct 2026, 20:02 UTC

Viridian Therapeutics Inc shares are advancing, maintaining a sharply higher trajectory since Monday's close despite an earlier pullback from a session high.

19 oct 2026, 20:02 UTC

Viridian Therapeutics Inc shares are sharply higher, continuing a trend of higher daily closes since Friday's close, amid mixed performance in the biotechnology sector.

16 oct 2026, 20:02 UTC

Viridian Therapeutics reports positive topline results from its REVEAL-2 Phase 3 trial for elegrobart, but faces increased competition from Roche's FDA-approved Enspryng.

15 oct 2026, 20:02 UTC

Viridian Therapeutics Inc shares are higher, continuing an upward trajectory since Wednesday's close, despite an earlier pullback from a session high.

14 oct 2026, 20:07 UTC

Viridian Therapeutics Inc shares are modestly higher, recovering from an early dip as the broader market also shows gains since Tuesday's close.

12 oct 2026, 20:06 UTC

Viridian Therapeutics Inc shares are declining, retreating from an earlier session high and remaining well below their 20-day moving average amid ongoing weakness.

9 oct 2026, 20:12 UTC

Viridian Therapeutics Inc shares advanced in after-market trading, holding a cumulative return of 1.19% since Friday's close.

8 oct 2026, 20:07 UTC

Viridian Therapeutics Inc shares are slightly higher, recovering from an earlier drop, but remain below their 20-day moving average and near the lower end of their one-month range.

7 oct 2026, 20:21 UTC

Viridian Therapeutics Inc declined during after-market hours, continuing a downward trend that began after Wednesday's close and remaining below its 20-day moving average.

6 oct 2026, 21:03 UTC

Viridian Therapeutics Inc is rising in after-market trading, advancing from a low of roughly flat to a high gain since Tuesday's close.

2 oct 2026, 20:07 UTC

Viridian Therapeutics Inc is advancing in today's trading session, gaining ground since Thursday's close, despite slightly retreating from an early peak.

1 oct 2026, 20:02 UTC

Viridian Therapeutics Inc. shares fell sharply amid growing anticipation for a follow-on program, marking a departure from recent higher daily closes.

29 sept 2026, 20:07 UTC

Viridian Therapeutics Inc. shares fell sharply, continuing a decline from Monday's close and remaining near the lower end of their one-month trading range.

25 sept 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, closing lower for the third consecutive session and remaining significantly below the 20-day moving average.

24 sept 2026, 20:07 UTC

Viridian Therapeutics Inc shares fell sharply, finishing significantly lower than Wednesday's close and well below its 20-day moving average.

23 sept 2026, 20:12 UTC

Viridian Therapeutics Inc saw modestly lower trading in after-market hours on Wednesday, remaining significantly below its 20-day moving average.

22 sept 2026, 19:34 UTC

RBC Capital raised its price target on Viridian Therapeutics to $38, maintaining an Outperform rating, as the stock holds gains above Monday's close despite earlier pulling back.

21 sept 2026, 20:12 UTC

Viridian Therapeutics Inc is trading modestly higher in after-market hours, maintaining stability with no significant movement since Monday's close.

17 sept 2026, 19:46 UTC

Viridian Therapeutics Inc shares fell sharply as the company navigates post-FDA approval dynamics for Lumvoa, remaining below its 20-day moving average.

16 sept 2026, 22:01 UTC

Viridian Therapeutics Inc is rising in after-market trading, moving from a low of 1.02% to a high of 1.20% since Wednesday's close.

15 sept 2026, 19:36 UTC

Viridian Therapeutics shares are lower today, continuing a decline since Monday amid broader market pressure from rising treasury yields. No specific news was identified.

14 sept 2026, 20:13 UTC

Viridian Therapeutics Inc. shares are higher in after-market hours, maintaining a cumulative return since Monday's close, despite a weaker performance backdrop.

11 sept 2026, 23:26 UTC

Viridian Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. Recent U.S. inflation data adds broader context.